|
|
Vol. 16.07 – 25 April, 2025
|
|
|
|
|
|
|
|
Researchers analyzed prostate cancer patients’ cohorts and found that XRCC1 expression varied widely, with many patients showing low XRCC1 expression. [NAR Cancer]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists identified bromodomain-containing protein 9 (BRD9) as a metabolic checkpoint for reprogramming cell metabolism to support tumor growth and impart a castration-resistant phenotype under metabolic and oxidative stress. [Cell Death & Disease]
|
|
|
|
|
|
Investigators found profound genomic instability in prostate cancer (PCa) cells with speckle-type POZ protein (SPOP) gene mutations and confirmed the sensitivity of SPOP-mutated PCa cells to olaparib-induced apoptosis.
[JCI Insight]
|
|
|
|
|
|
Scientists designed a biomimetic nanocarrier composed of zeolitic imidazolate framework-8 (ZIF-8) encapsulating doxorubicin as the core and a shell of exosome-like nanoparticles derived from Cucurbita moschata. This design enhances safety and addresses some exosome limitations.
[Journal of Materials Chemistry B]
|
|
|
|
|
|
Investigators explored the molecular mechanisms through which valosin-containing protein/p97 contributed to the progression of neuroendocrine prostate cancer.
[The Prostate]
|
|
|
|
|
|
Scientists explored the potential of stachydrine hydrochloride in addressing paclitaxel resistance within castration-resistant prostate cancer. [Naunyn-Schmiedebergs Archives of Pharmacology]
|
|
|
|
|
|
|
|
The authors summarize the understood mechanisms of action of androgen receptor (AR) and its interactions with exercise, specifically on outcomes of body composition and muscle function, and the global- and tissue-specific role of AR in regulating skeletal muscle, adipose, and bone morphology.
[Biology of Sex Differences]
|
|
|
|
|
|
The future of mCRPC treatment likely lies in a personalized, multimodal approach that integrates PSMA-based RLTs, BiTEs, and complementary therapies at earlier disease stages. [Current Treatment Options In Oncology]
|
|
|
|
|
|
|
|
Cardiff Oncology, Inc. recieved U.S. patent No. 12,263,173 covering the method of using onvansertib in combination with bevacizumab (bev) in any line of therapy for the treatment of metastatic colorectal cancer (mCRC) patients who have not previously been treated with bev. [Cardiff Oncology]
|
|
|
|
|
|
|
|
May 26-28, 2025 Heidelberg, Germany & Online
|
|
|
|
|
|
|
|
|
|
|
Ulster University – Coleraine, Northern Ireland, United Kingdom
|
|
|
|
|
|
|
Technische Universität Dresden – Dresden, Germany
|
|
|
|
|
|
|
Vancouver Prostate Centre – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
Macon & Joan Brock Virginia Health Sciences at Old Dominion University – Norfolk, Virginia, United States
|
|
|
|
|
|